Sugi Predict

Sugi Predict / Compounds / SCHEMBL2824475

SCHEMBL2824475

SCHEMBL2824475

NCCCC(O)C(N)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 1/20 0.50
▸ CPB2 Q96IY4 4/20 0.47
▸ RNPEP Q9H4A4 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ SLCO1B1 Q9Y6L6 1/20 0.43
▸ TRPV1 Q8NER1 1/20 0.39
▸ TRPA1 O75762 1/20 0.39
▸ GABRR1 P24046 3/20 0.38
▸ GABRR3 A8MPY1 1/20 0.37
▸ GABRP O00591 1/20 0.37
▸ GABRD O14764 1/20 0.37
▸ HDAC3 O15379 1/20 0.37
▸ GABBR2 O75899 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ GABRA1 P14867 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ GABRB1 P18505 1/20 0.37
▸ GABRG2 P18507 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3948254 1.00 GSR (0.50) GSRCPB2RNPEPUSP2SLCO1B1
SCHEMBL16732008 1.00 GSR (0.50) GSRCPB2RNPEPUSP2SLCO1B1
SCHEMBL503258 1.00 GSR (0.50) GSRCPB2RNPEPUSP2SLCO1B1
SCHEMBL358290 1.00 GSR (0.50) GSRCPB2RNPEPUSP2SLCO1B1
Hydrochloric Acid SCHEMBL16760214 0.98 GSR (0.48) GSRCPB2RNPEPUSP2SLCO1B1
Hydrochloric Acid SCHEMBL16760213 0.98 GSR (0.48) GSRCPB2RNPEPUSP2SLCO1B1
Hydrochloric Acid SCHEMBL7107024 0.96 GSR (0.47) GSRCPB2RNPEPUSP2SLCO1B1
Hydrochloric Acid SCHEMBL751303 0.96 GSR (0.47) GSRCPB2RNPEPUSP2SLCO1B1
SCHEMBL16731992 0.86 USP2 (0.46) GSRCPB2RNPEPUSP2SLCO1B1
SCHEMBL2482513 0.86 USP2 (0.46) GSRCPB2RNPEPUSP2SLCO1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287383-A1 PYRROLYSYL-tRNA SYNTHETASE VARIANTS AND USES THEREOF ENGENES BIOTECH GMBH (AT) 2023-09-14 — — US claimed
EP-4232590-A1 SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS Feldan Bio Inc. (CA) 2023-08-30 — — EP claimed
EP-4229207-A1 PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION Feldan Bio Inc. (CA) 2023-08-23 — — EP claimed
EP-4176050-A1 PYRROLYSYL-TRNA SYNTHETASE VARIANTS AND USES THEREOF enGenes Biotech GmbH (AT) 2023-05-10 — — EP claimed
WO-2022082315-A1 SHUTTLE AGENT PEPTIDES OF MINIMAL LENGH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS FELDAN BIO INC. (CA) 2022-04-28 — — WO claimed
WO-2022077121-A1 PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION FELDAN BIO INC. (CA) 2022-04-21 — — WO claimed
WO-2022003142-A1 PYRROLYSYL-tRNA SYNTHETASE VARIANTS AND USES THEREOF ENGENES BIOTECH GMBH (AT) 2022-01-06 — — WO claimed
WO-2018185222-A1 AMINOACYL TRNA SYNTHETASES AND ORTHOGONAL TRNAS ACIB GMBH - AUSTRIAN CENTRE OF INDUSTRIAL BIOTECHNOLOGY (AT) 2018-10-11 — — WO claimed
EP-2760881-B1 NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS NOSOPHARM (FR) 2017-11-01 — — EP claimed
US-9260481-B2 Peptide derivatives as antibiotics NOSOPHARM (FR) 2016-02-16 — — US claimed
US-20150175659-A1 Peptide Derivatives as Antibiotics INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 2015-06-25 — — US claimed
EP-2760881-A1 NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS Nosopharm (FR) 2014-08-06 — — EP claimed
WO-2013045600-A1 NOVEL PEPTIDE DERIVATIVES AS ANTIBIOTICS NOSOPHARM (FR) 2013-04-04 — — WO claimed
US-20030208050-A1 Nucleoside derivatives JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) 2003-11-06 — — US claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 — — US claimed
EP-4725952-A1 COMPOUNDS COMPRISING NON-CANONICAL AMINO ACIDS AND USES THEREOF ETH Zurich (CH) 2026-04-15 — — EP disclosed
US-20240075142-A1 Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy LENTIGEN TECHNOLOGY, INC. 2024-03-07 — — US disclosed
EP-0787010-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-06 — — EP disclosed
WO-1996012499-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-05-02 — — WO disclosed
US-4595532-A N-(substituted-methyl)-azetidin-2-ones UNIVERSITY OF NOTRE DAME DU LAC (US) 1986-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030208050-A1 Nucleoside derivatives RIMKLA, MTHFD1, AADAT GSR 1541/4885CPB2 1928/4885RNPEP 229/4885
US-20150175659-A1 Peptide Derivatives as Antibiotics VIP, NGLY1, NRDC GSR 3128/4885CPB2 1264/4885RNPEP 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.